Evotec Reports H1 2025 Results: Strategy for Sustainable Growth Progressing Ahead of Plan

Evotec SE reported H1 2025 results with group revenues of €371.2m, down 5% YoY, and adjusted EBITDA of €(1.9)m. The company's strategy for sustainable growth is progressing as planned, with improving revenue mix and ahead-of-plan cost reductions. Discovery & Preclinical Development revenues decreased by 11% to €269m, while Just-Evotec Biologics revenues increased by 16% to €102.2m. Evotec expects to exceed its cost savings targets and continues to see strong progress in collaborations with Bristol Myers Squibb and the evolution of its partnership with Sandoz.

Evotec SE (NASDAQ:EVO) reported its H1 2025 financial results, showing a 5% year-over-year (YoY) decline in group revenues to €371.2 million. The company's strategy for sustainable growth is progressing as planned, with improving revenue mix and ahead-of-plan cost reductions. Discovery & Preclinical Development (D&PD) revenues decreased by 11% to €269.0 million, reflecting persistent softness in the drug discovery market. Conversely, Just-Evotec Biologics (JEB) revenues increased by 16% to €102.2 million, driven by a broadened customer base.

The company's adjusted EBITDA loss was €1.9 million, only slightly worse than last year's €0.5 million loss, despite the revenue decline. Evotec expects to exceed its cost savings targets, supporting its full-year 2025 guidance of €30-50 million in adjusted EBITDA.

Significant strategic progress includes key collaborations with Bristol Myers Squibb (BMS), resulting in milestone payments totaling $95 million. Evotec also signed a non-binding agreement to sell its J.POD biologics facility in Toulouse for approximately $300 million, marking a strategic shift towards an asset-lighter model.

Management expects the market recovery for discovery services to begin as early as 2026, maintaining full-year 2025 revenue guidance of €760-800 million. The guidance suggests H2 will show sequential improvement as cost measures take effect and collaboration revenues accelerate.

For more detailed information and financial tables, please refer to the half-year report published on the Evotec website [1].

References:
[1] https://www.stocktitan.net/news/EVO/evotec-se-reports-h1-2025-results-strong-progress-on-strategy-h8hq7an8cthi.html
[2] https://www.nasdaq.com/press-release/evotec-se-reports-h1-2025-results-strong-progress-strategy-execution-2025-08-13